Page 90 - Read Online

Ma et al. Hepatoma Res. 2026;12:43 Page 21 of 22

36. Zhang S, Zhong BY, Zhang L, Wang WS, Ni CF. Transarterial chemoembolization failure/refractoriness: a scientific concept or pseudo-
proposition. World J Gastrointest Surg. 2022;14:528-37. DOI PubMed PMC
37. Gao X, Sun Y, Huang J, Xu L, Huang H, Yang Z. Adrenomedullin orchestrates treatment resistance in hepatocellular carcinoma via
immune microenvironment remodeling. Front Genet. 2025;16:1721263. DOI PubMed PMC
38. Li J, Liu Y, Zheng R, Qu C, Li J. Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure.
Life Sci. 2024;342:122540. DOI PubMed
39. Liu CY, Wang MF, Xu XY, et al. Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint
inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial
chemoembolization. Ther Adv Med Oncol. 2025;17:17588359251347363. DOI PubMed PMC
40. Li R, Liu J, Ye F, et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver
injury in HCC. J Hepatol. 2026;84:808-22. DOI PubMed
41. Saito N, Tanaka T, Nishiohuku H, et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage
hepatocellular carcinoma with preserved liver function. Hepatol Res. 2020;50:1176-85. DOI PubMed
42. Hiraoka A, Kumada T, Kudo M, et al. ; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular
carcinoma experts from 48 clinics). Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in
patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig Dis. 2017;35:602-10. DOI PubMed
43. Chan SL, Sun HC, Xu Y, et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive
strategies from prevention to treatment. Lancet. 2025;406:731-78. DOI PubMed
44. Lim RY, Koh B, Ng CH, et al. ; Liver Cancer Research Network. Hepatocellular carcinoma surveillance and survival in a contemporary
Asia-Pacific cohort. JAMA Netw Open. 2025;8:e2520294. DOI PubMed PMC
45. Kim BK, Shim JH, Kim SU, et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization:
development of a prediction model. Liver Int. 2016;36:92-9. DOI PubMed
46. Wang Q, Xia D, Bai W, et al. ; China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates
with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019;70:893-903. DOI PubMed
47. Xia D, Bai W, Wang Q, et al. ; China HCC-TACE study group. Tumor burden with AFP improves survival prediction for TACE-treated
patients with HCC: an international observational study . JHEP Rep. 2025;7:101216. DOI PubMed PMC
☆
48. Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular
carcinoma: a response-based approach. Hepatology. 2020;72:198-212. DOI PubMed PMC
49. Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with
hepatocellular carcinoma. Hepatology. 2013;57:2261-73. DOI PubMed
50. Hucke F, Sieghart W, Pinter M, et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with
hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118-26. DOI PubMed
51. Chen L, Ni CF, Chen SX, et al. A modified model for assessment for retreatment with transarterial chemoembolization in Chinese
Hepatocellular Carcinoma Patients. J Vasc Interv Radiol. 2016;27:1288-97. DOI PubMed
52. Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with
intermediate stage hepatocellular carcinoma. J Hepatol. 2014;61:1287-96. DOI PubMed
53. Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol.
2015;62:855-62. DOI PubMed
54. Shen L, Zeng Q, Guo P, et al. Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based
on time-series data. Nat Commun. 2018;9:2230. DOI PubMed PMC
55. Dang M, Wang S, Peng F, et al. Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in
hepatocellular carcinoma. Hepatol Commun. 2025;9:e0652. DOI PubMed PMC
56. Wei R, Liu Z, Ju L, et al. Using machine learning to predict advanced-stage progression of intermediate-stage hepatocellular carcinoma
after transarterial chemoembolization. Radiol Imaging Cancer. 2025;7:e250034. DOI PubMed PMC
57. Song L, Zhu C, Shi Q, et al. Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against
hepatocellular carcinoma progression. EBioMedicine. 2024;109:105436. DOI PubMed PMC
58. Gong F, Zheng L, Xu J, et al. Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular
carcinoma: from animal models to a pilot clinical study. Sci Adv. 2025;11:eadv0885. DOI PubMed PMC
59. Wu Z, Ouyang S, Gao J, et al. Role of radiomics-based multiomics panel in the microenvironment and prognosis of hepatocellular
carcinoma. Acad Radiol. 2025;32:1961-70. DOI PubMed
60. Wang G, Ding F, Chen K, et al. CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor
microenvironment. J Transl Med. 2024;22:683. DOI PubMed PMC